申请人:MANROS THERAPEUTICS
公开号:US10561661B2
公开(公告)日:2020-02-18
A method for treatment of disease by reduction in macrophages-mediated bacterial killing, including administration to patients in need a compound of formula (I):
wherein A is N or CH; B is NO, or S; R1 is H, (C1-C4)alkyl group, methyl(C1-C6)cycloalkyl group or (C1-C6)cycloalkyl group; R2 is an aryl, arylmethyl group or methylheteroaryl group as methylpyridine and methylthiophene; R3 is absent when B is O or S, or is H or (C1-C4)alkyl group when B is N; R4 is (C1-C5)alkyl group or (C1-C4)cycloalkyl group, groups bearing a carboxylic acid group, and (C1-C5)alkyl group or (C1-C4)cycloalkyl substituted by hydroxyl group, halogen group or methoxy group, when B is N, R3 and R4 can together form a 5- or 6-membered heterocycle substituted by carboxylic acid group, substituted by a halogen atom, hydroxyl group, methoxy group or hydroxymethyl group, or pharmaceutically acceptable salt. Also provided are new compounds relating to this use.
一种通过减少巨噬细胞介导的细菌杀伤来治疗疾病的方法,包括向有需要的患者施用式 (I) 化合物:
其中 A 是 N 或 CH;B 是 NO 或 S;R1 是 H、(C1-C4)烷基、甲基(C1-C6)环烷基或(C1-C6)环烷基;R2 是芳基、芳甲基或甲基杂芳基,如甲基吡啶和甲基噻吩;当 B 是 O 或 S 时,R3 不存在,当 B 是 N 时,R3 是 H 或(C1-C4)烷基;R4是(C1-C5)烷基或(C1-C4)环烷基、带有羧酸基团的基团,以及被羟基、卤素基团或甲氧基取代的(C1-C5)烷基或(C1-C4)环烷基,当B为N时,R3和R4可共同形成被羧酸基团取代的、被卤素原子、羟基、甲氧基或羟甲基取代的5或6元杂环,或药学上可接受的盐。此外,还提供了与该用途有关的新化合物。